Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
21 hedge funds and large institutions have $51.6M invested in Soleno Therapeutics in 2019 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 3 closing their positions.
236% more capital invested
Capital invested by funds: $15.4M → $51.6M (+$36.2M)
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
17% more funds holding
Funds holding: 18 → 21 (+3)
7.29% more ownership
Funds ownership: 32.41% → 39.7% (+7.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$7.3M |
| 2 |
A
Abingworth
London,
United Kingdom
|
+$3.92M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$506K |
| 4 |
BC
Birchview Capital
Burlington,
Vermont
|
+$460K |
| 5 |
JGC
J. Goldman & Co
New York
|
+$355K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$251K |
| 2 |
Renaissance Technologies
New York
|
-$43.7K |
| 3 |
Bank of New York Mellon
New York
|
-$24K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5.04K |
SLNO Hedge Fund Activity: Q4 2019 in Review
21 of the 5,093 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q4 2019, worth a combined $51.6M — up 236% from $15.4M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new SLNO positions and 3 closed out — a net gain of 3 holders — while 6 added to existing stakes and 7 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $7.3M. The largest seller was 683 Capital Management, cutting an estimated $251K.
- 21 institutional investors held Soleno Therapeutics (SLNO) as of Q4 2019, up from 18 in Q3 2019.
- Funds reported $51.6M of Soleno Therapeutics stock for Q4 2019, up 236% quarter-over-quarter.
- 6 funds opened new Soleno Therapeutics positions in Q4 2019 and 3 closed out, a net change of +3 holders.
- The largest Soleno Therapeutics buyer in Q4 2019 was Nantahala Capital Management, an estimated $7.3M added.
- The largest Soleno Therapeutics seller in Q4 2019 was 683 Capital Management, an estimated $251K sold.
Based on aggregated 13F filings for Q4 2019.